Get a glimpse into our company and investor data—powered by the PitchBook Platform
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
You’re viewing a free company profile from the PitchBook Platform. To explore BioMarin Pharmaceutical’s full profile, request a free trial.
52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
---|---|---|---|---|---|
$62.88 - $100.13 | $14.2B | $79.92 | -$0.24 | 1.49M | 180M |
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
---|---|---|---|---|
Enterprise Value | 12,214,017 | 14,918,961 | 15,569,086 | 13,888,229 |
Revenue | 1,602,819 | 1,491,212 | 1,313,646 | 1,116,854 |
EBITDA | (21,647) | (29,811) | 76,115 | (705,493) |
Net Income | (42,522) | (77,211) | (117,042) | (630,210) |
Total Assets | 4,558,128 | 4,427,128 | 4,633,125 | 4,023,690 |
Total Debt | 853,841 | 830,417 | 1,174,470 | 683,239 |
Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
---|
This information is reserved for PitchBook Platform users. To explore BioMarin Pharmaceutical‘s full profile, request access.
Request full access to PitchBookCompany Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Alexion | Formerly VC-backed | Boston, MA | 0000 | 000000&0 | ||
0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 0000 | 00000 |
0000000 0000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000000 | 00000 |
0000000000 0000000 | Formerly VC-backed | Novato, CA | 000 | 00000 | 00000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 00000000 | 00.000 |
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000 000000 & 000 | 01-Oct-2015 | 000000000 00000 00 | 00000 | Other Business Products and Services | 0000-0000000 00000000 |
00000000 | 29-Jan-2015 | 000000000000000000 | 00000 | Biotechnology | 0000-0000000 00000000 |
00000000 000000000 | 07-Jan-2013 | 000000000000000000 | 00000 | Pharmaceuticals | |
000000 (000000000 | 01-Aug-2011 | 000000000 00000 00 | 000.00 | Buildings and Property | 0000-0000000 00000000 |
ZyStor Therapeutics | 17-Aug-2010 | Merger/Acquisition | 00000 | Biotechnology | 0000-0000000 00000000 |
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
00 00000 000000000 | 16-Jan-2009 | 0000 | 00.00 | Completed |
|
Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
---|
This information is reserved for PitchBook Platform users. To explore BioMarin Pharmaceutical‘s full profile, request access.
Request full access to PitchBook10 Former Executives
You’re viewing 5 of 20 executives. Get the full list »Name | Representing | Role | Since | Contact Info |
---|---|---|---|---|
Alan Lewis Ph.D | Self | Board Member | 000 0000 | |
Bryan Lawlis Ph.D | Self | Board Member | 000 0000 | |
David Pyott | Self | Board Member | 000 0000 | |
Dennis Slamon Ph.D | BioMarin Pharmaceutical | Board Member | 000 0000 | |
Elaine Heron Ph.D | Self | Board Member | 000 0000 |
7 Former Board Members
You’re viewing 5 of 16 board members. Get the full list »